Abstract

BackgroundAlthough anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency of the initial drug or prescribing...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0106 Rituximab after first anti-TNF failure is more efficient with high impact in reducing time and costs to achieve superior rates of low disease activity and remission
I Ancuta ... M Parvu
Annals of the Rheumatic Diseases | VOL. 71
I Ancuta, et. al.I Ancuta ... M Parvu
01 Jun 2013
A1.27 Serum rituximab level and other predictors for good eular response before re-treatment in rheumatoid arthritis
...
Annals of the Rheumatic Diseases | VOL. 73
, et. al. ...
31 Jan 2014
THU0107 CCL19, a chemokine involved in B-cell trafficking, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis: Results from the smart study
J Sellam ... J Tebib
Annals of the Rheumatic Diseases | VOL. 71
J Sellam, et. al.J Sellam ... J Tebib
01 Jun 2013
FRI0169 Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration
K Chatzidionysiou ... E Lie
Annals of the Rheumatic Diseases | VOL. 74
K Chatzidionysiou, et. al.K Chatzidionysiou ... E Lie
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.